Top Story

ALLY-1: transplant patients, those with cirrhosis achieve SVR12 with daclatasvir, sofosbuvir

April 26, 2015

VIENNA — A regimen containing Sovaldi and daclatasvir was associated with favorable 12-week sustained virologic response rates in a cohort of patients with advanced cirrhosis, according to data presented at the 2015 International Liver Congress.

“This 12-week pangenotypic regimen of daclatasvir, sofosbuvir and ribavirin is generally safe, well-tolerated and efficacious across multiple genotypes,” Fred Poordad, MD, of the Texas Liver Institute and University of Texas Health Science Center in San Antonio, said during the Late Breakers session.

Meeting News Coverage

Oligonucleotide injection reduced HCV viral load

April 26, 2015
VIENNA — Injection of an oligonucleotide with activity against microRNA-122 led to undetectable viral load in a cohort of HCV patients of multiple genotypes…
Anupama Subramony, MD Meeting News Coverage

Use of PCR among children with acute respiratory infections may reduce resource utilization

April 25, 2015
SAN DIEGO —Among children hospitalized for acute respiratory infections, using real-time PCR testing increased the number of isolation days but reduced antibiotic…
ANRS CO22: SVR4 rates near 100% for sofosbuvir/daclatasvir in genotype 1 Meeting News Coverage

ANRS CO22: SVR4 rates near 100% for sofosbuvir/daclatasvir in genotype 1

April 25, 2015
VIENNA — Patients treated with regimens containing Sovaldi and daclatasvir achieved encouraging 4-week sustained virologic response rates, according to data…
Meeting News Coverage

RUBY-I: Preliminary study shows safety of 3D + ribavirin in CKD

April 25, 2015
VIENNA — A small cohort of patients with chronic kidney disease demonstrated favorable tolerability outcomes with the Viekira Pak, according to data presented…
More News Headlines »
CME
Regimen Selection in HIV

Regimen Selection in HIV: Considering New Options to Optimize Outcomes
Monograph

This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

More than 2 decades into the antiretroviral therapy (ART) era, numerous options are available for HIV treatment. The…
More »
Meeting News Coverage Video
VIDEO: Effectiveness of inactivated vs. live flu vaccine currently unclear

VIDEO: Effectiveness of inactivated vs. live flu vaccine currently unclear

April 24, 2015
BETHESDA, Md. — Richard K. Zimmerman, MD, of the University of Pittsburgh, explains the results of his study…
More »
CME
Infectious Disease Case Consults

The Patient at Risk for HIV Infection

No commercial support for this activity.

This CME activity will focus on the utilization of PrEP in patients at risk for developing HIV infection supplemented…
More »
morganatic-roan
morganatic-roan